Introduction
============

Diabetic nephropathy (DN) represents one of the major chronic complications of diabetes, causing a progressive decline in glomerular filtration rate ([@b1-etm-0-0-8188]). In the process of DN initiation and progression, abnormal activation of the renin angiotensin system (RAS), both locally and systemically, generates functional abnormalities in the vasculature. This leads to endothelial dysfunction and extracellular matrix deposition, contributing to sclerosis, fibrosis and progressive DN ([@b2-etm-0-0-8188],[@b3-etm-0-0-8188]). Angiotensin II is known to cause endothelial damage and dysfunction, which then promotes reactive oxygen species (ROS) production and NF-κB activation, potentiating hypertension-induced injury to the glomerular filtration barrier ([@b4-etm-0-0-8188],[@b5-etm-0-0-8188]). Various studies have demonstrated that angiotensin II is a proinflammatory, pro-oxidant peptide that contributes substantially to kidney tissue injury beyond the hemodynamic influences on vascular tone and intraglomerular pressure ([@b6-etm-0-0-8188],[@b7-etm-0-0-8188]). In turn, angiotensin-converting enzyme inhibitors (ACEIs) can inhibit the generation of angiotensin II, thereby effectively blocking ROS, whilst also reducing blood pressure and urinary protein excretion, delaying the deterioration of renal function. These effects have been confirmed by a large number of experiments, and ACEIs have accordingly been used as basic drugs to treat DN in the clinic ([@b8-etm-0-0-8188],[@b9-etm-0-0-8188]). In particular, fosinopril (FP) has been revealed to have significant benefits in the early stages of DN in clinical trials ([@b10-etm-0-0-8188]). However, the mechanism of action of ACEIs or FP in mediating renal protection is not yet fully understood.

Previous studies have demonstrated that the pathogenesis of DN is very complex ([@b1-etm-0-0-8188],[@b11-etm-0-0-8188],[@b12-etm-0-0-8188]). Notably, one of the best animal models available to study DN is the Otsuka Long-Evans Tokushima Fatty (OLETF) rat ([@b13-etm-0-0-8188]). OLETF rats can spontaneously develop late-onset hyperphagia, mild obesity, late-onset hyperglycemia, hypertension, dyslipidemia and advanced DN. At 12--20 weeks of age, OLETF rats exhibit mild obesity and hyperinsulinemia. Late-onset hyperglycemia is noted by 18 weeks of age. At 22 weeks of age, OLETF rats develop overt albuminuria and at the age of 54 weeks, advanced renal changes such as macroalbuminuria, nodular lesions, diffuse glomerulosclerosis and tubulointerstitial fibrosis are present, which is comparable to the symptoms of human DN ([@b14-etm-0-0-8188]). Long-Evans Tokushima Otsuka (LETO) rats are available as a normal control for OLETF rats, as they carry a similar genetic background but do not spontaneously develop diabetes ([@b15-etm-0-0-8188]).

Therefore, to investigate the mechanisms of action of ACEIs in the treatment of DN, the present study examined the effects of the ACEI FP on protein expression in the renal cortex of OLETF rat using mass spectrometry-based profiling. By incorporating a research model with a consistent genetic background, the experimental design reduced the difficulty of protein analysis inherent in a natural population with obvious heterogeneity. In addition, kidney cortex proteins were separated into soluble and insoluble protein fractions to further overcome the complexity of the OLETF rat kidney cortex proteome. The results of the current study may elucidate novel concepts regarding the underlying mechanism of FP in DN.

Materials and methods
=====================

### Animals and experimental design

Four-week-old male LETO rats (n=18; weight, 164±6 g) and age-matched OLETF rats (n=24; weight, 207±19 g) that were provided by the Tokushima Research Institute (Otsuka Pharmaceutical). All rats were housed at 22±3°C and 50±10% humidity using a 12-h light/dark cycle. All animals were given free access to standard rat chow and water.

Three groups of rats at 12 weeks of age were prepared as follows: i) Non-diabetic LETO rats provided with distilled water (LETO control; n=18); ii) diabetic OLETF rats provided with distilled water (OLETF control; n=12); and iii) OLETF rats administered FP (Monopril; Bristol-Myers Squibb) at 0.833 mg/kg body weight/day (OLETF + FP; n=12). FP was dissolved in distilled water and administered once daily by intragastric administration. At 36 weeks of age, 10 rats from the LETO control group and 7 rats from the other two groups were euthanized with an intraperitoneal injection of pentobarbital (200 mg/kg). The remaining rats in each group (8 LETO controls and 5 from each of the other groups) were sacrificed at 56 weeks of age. After the rats were sacrificed, the kidneys were removed and separated into two pieces for histopathological examination and proteomic analysis. The present study was approved by the Ethics Committee of the China-Japan Friendship Institute of Clinical Medicine (no. ZR05016) and performed in accordance with the Guiding Principles for the Care and Use of Laboratory Animals ([@b16-etm-0-0-8188]).

### MTT assay

An MTT assay was performed to analyze whether FP damaged renal tubular NRK-52E cells (Cell Resource Center of Shanghai Institutes for Biological Science) under normal and high glucose conditions. Cells were seeded into 96-well plates (2×10^3^ cells/well) in 200 µl culture medium (DMEM (Gibco; Thermo Fisher Scientific, Inc.; cat. no. 31600-034) supplemented with 5% fetal bovine serum (Gibco; Thermo Fisher Scientific, Inc.; 16000-044)) treated with different FP concentrations (0, 0.05, 0.10, 0.20, 0.41, 0.83, 1.66, 3.33, 6.66, 13.32 and 26.65 mg/ml) under normal (5 mM) and high (30 mM) glucose media for 48 h at 37°C. Following treatment, cells were washed twice with PBS and 20 µl MTT (2 mg/ml) was subsequently added into each well. Cells were further incubated for 4 h at 37°C, after which DMSO was added into each well to dissolve formazan crystals. Absorption was determined at a wavelength 490 nm using a Bio-Rad 680 microplate reader (Bio-Rad Laboratories, Inc.).

### Determination of body weight, blood glucose and urinary protein

The body weights of the rats were measured at 4-week intervals. Blood samples from the tail vein were taken at 4-week intervals and blood glucose levels were measured using a One Touch Ultrablood glucose monitoring system (LifeScan, Inc.). Rats were housed individually in metabolic cages (Suzhou Fengshi Laboratory Animal Equipment Co., Ltd.) for urinary collection for 24 h at 4-week intervals.

### Histological examination of the kidney

Sections of kidney tissue were removed and immediately fixed in 10% phosphate buffered formalin solution at room temperature for 24 h and embedded in paraffin for further histological and immunohistochemical analysis. Sections (3 µm) from each sample were cut and stained with periodic acid Schiff\'s stain for evaluation of the degree of glomerulosclerosis, defined as a thickening of the basement membrane and mesangial expansion from 40 glomeruli in each section at ×400 magnification ([@b17-etm-0-0-8188]). Tubulointerstitial and vascular damage were assessed on periodic acid Schiff-stained paraffin sections at ×100 magnification using a similar scoring system (0--4) as previously described ([@b18-etm-0-0-8188]). The observer was blinded to all tissue samples.

### Immunohistochemistry

Kidney injury molecule-1 (KIM-1) immunohistochemical staining was performed to analyze whether FP caused OLETF renal damage. All procedures were performed in accordance with the Elivision™ Plus Two-step System PV-6000 kit protocol (Zymed; Thermo Fisher Scientific, Inc.; cat. no. PV6000). Paraffin sections (3 µm thick) as aforementioned were deparaffinized in xylene and rehydrated in descending alcohol series, after which endogenous enzyme activity was blocked via incubation in 3% hydrogen peroxide for 10 min at room temperature. Antigen retrieval was performed by incubating samples with 0.01 mol/l sodium citrate buffer (pH 6.0) at 115°C for 1.5 min. Tissue sections were subsequently incubated with primary polyclonal antibodies against KIM-1 (Boster Biological Technology; cat. no. BA35317; 1:100) overnight at 4°C. After washing with PBS, sections were incubated with secondary antibodies (included in the Dako Elivision™ Plus Two-step System PV-6000 kit; Zymed; Thermo Fisher Scientific, Inc,) for 25 min at 37°C. The signal was subsequently visualized using the Diaminobenzidine. Following counterstaining with hematoxylin for 15 min at room temperature, positive immunostaining was scored by two blinded experienced pathologists. Immunohistochemistry results were evaluated using an Olympus BX53 upright light microscope and scored by examining 10 random representative fields at a 400× magnification. The staining intensity of each visual field was graded from 0 to 3+, as descried by Zhang ([@b19-etm-0-0-8188]).

### Extraction of renal cortical soluble and insoluble protein fractions

The method of extraction of soluble and insoluble protein was based on a previously described protocol with some modifications ([@b20-etm-0-0-8188]). Briefly, the renal cortical tissue samples from the LETO, OLETF and OLETF treated with FP groups were ground into powder in liquid nitrogen individually. Soluble lysis buffer \[40 mM Tris, pH 7.5; 1% dithiothreitol; 1% IPG buffer, pH 3--10; and protease inhibitor cocktail (Roche Diagnostics)\] were added to dissolve the powder, and the mixture was then centrifuged at 40,000 × g at 4°C for 30 min to separate the soluble and insoluble fractions. The soluble fraction was further centrifuged at 40,000 × g at 4°C for 30 min to separate out any remaining insoluble content. The insoluble fraction was washed twice with soluble lysis buffer (details as aforementioned) to wash out any soluble proteins. The insoluble pellet was suspended in insoluble lysis buffer (40 mM Tris, pH 7.5; 7 M urea; 2 M thiourea; 4% CHAPS; 1% dithiothreitol; 1% IPG buffer, pH 3--10; and complete protease inhibitor cocktail) and then subjected to ultrasound homogenization at 5 sec pulsed intervals at 20 kHz for 1 min on ice. The homogenized pellet was then put on ice for 30 min and the solution was spun at 40,000 × g at 14°C for 30 min to separate out any insoluble content. Protein concentration was determined using the Bradford protein assay on a GeneQuant 1300 spectrometer (GE Healthcare Life Sciences). The protein extracts were stored at −80°C for subsequent two-dimensional electrophoresis (2-DE) analysis.

### 2-DE and matrix assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS)

Each prepared soluble and insoluble protein was separated by 2-DE individually and the differentially expressed proteins were identified by MALDI-TOF MS using a method described previously ([@b21-etm-0-0-8188]). In brief, samples of 1.3 mg soluble or insoluble protein were loaded on an immobilized pH gradient gel strip (pH 3--10 NL, 24 cm; GE Healthcare) using the in-gel rehydration mode. Proteins were separated by first dimensional separation (Ettan IPGphor 3 Isoelectric Focusing Unit; GE Healthcare), and 13% total monomer concentration and 3% weight percentage of crosslinker second dimensional separation (Ettan DALT II system; GE Healthcare). The separated protein spots were visualized using colloidal Coomassie blue staining according to the manufacturer\'s protocol (GE Healthcare), and the resultant images were analyzed using ImageMaster 2D Platinum 6.0 software (GE Healthcare), according to manufacturer\'s protocol. Statistical analysis was carried out using the t-test and false discovery rate as described by Biron *et al* ([@b22-etm-0-0-8188]). The differentially expressed protein spots were cut manually from the gels with a stainless-steel scalpel. The in-gel digestion and MALDI-TOF MS of each excised protein spot were performed by the National Center of Biomedical Analysis (Beijing, China).

### Database search

The obtained MS data were identified by using the Mascot search engine ([www.matrixscience.com/cgi/search_form.pl?FORMVER=2&SEARCH=PMF](www.matrixscience.com/cgi/search_form.pl?FORMVER=2&SEARCH=PMF)) according to the specific peptide mass fingerprints (PMF). Identified proteins were further checked for reliability following the criteria by Biron *et al* ([@b22-etm-0-0-8188]) as follows: i) molecular weight search Score \>60 (calculated as −10\*Log (P); P\<0.05, default threshold); ii) proportion of the theoretical sequence of the protein covered by MS data ≥20%; and iii) compared with theoretical values, a molecular mass variation \<30% and isoelectric point variation \<2.0. Each identified candidate protein entry was traced to its corresponding official gene name using the Protein Information Resource (Georgetown University Medical Center).

### Functional classification of differentially expressed proteins

To obtain an overview of the differentially expressed protein functions of the OLETF rat kidney cortex, the online tool DAVID Bioinformatics Resources 6.7 (<https://david-d.ncifcrf.gov/>) was used to perform enrichment analysis using gene ontology (GO) terms and KEGG pathways ([@b23-etm-0-0-8188]). The threshold was set as P\<0.05 to explore the overrepresentation of biological terms and signaling pathways.

### Western blot analysis

As not all identified proteins had commercial antibodies and due to economic limitations, heat shock protein family A member 9 (Hspa9) and glutathione peroxidase 3 (Gpx3) were selected as representative proteins and examined by western blot analysis to confirm their expression alterations. Protein samples from 2-DE analysis (15 µg) were separated via SDS-PAGE using a 12% polyacrylamide gel and electro-transferred to a nitrocellulose membrane in a Trans-Blot^®^ Semi-dry Electrophoretic Transfer Cell (Bio-Rad Laboratories, Inc.). Nonspecific bands were blocked in TBS-T (25 mM Tris, 150 mM NaCl and 0.05% Tween-20; pH 7.5) containing 5% skimmed milk at room temperature for 1 h. Membranes were subsequently incubated with a primary antibody against Hspa9 (Santa Cruz Biotechnology, Inc.; 1:1,000; cat. no. SC-133137), Gpx3 (Abcam; 1:1,000; cat. no. ab256470) and β-actin (Tianjin Sungene Biotech Co.; 1:5,000; cat. no. KM9001) overnight at 4°C followed by incubation with an anti-mouse (Jackson ImmunoResearch Laboratories, Inc.; 1:3,000; cat. no. 115-035-003) or anti-rabbit IgG (Jackson, 1:3,000; cat. no. 111-035-003) horseradish peroxidase-conjugated secondary antibodies at room temperature for 1 h. The immunocomplexes were visualized by enhanced chemiluminescence using the Amersham ECL Western Blotting Detection kit (GE Healthcare). The signals were acquired by the chemiDoc™XR+ molecular imager (Bio-Rad Laboratories, Inc.) and then quantified using Quantity-One 4.31 software (Bio-Rad Laboratories, Inc.).

### Statistical analysis

SigmaPlot 12.5 (Systat Software, Inc.) was used to analyze data and determine statistical differences. Each experiment was at independently replicated 3 times and data were presented as the mean ± standard deviation. Data that met the criteria for parametric tests were analyzed by Student\'s t-test (two groups) or by a one-way ANOVA and a subsequent Bonferroni post-hoc test (more than two groups). Groups of data that failed tests for normality and equal variance were analyzed by the nonparametric Kruskal-Wallis test followed by Dunn\'s test. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### FP treatment lowers 24-h urinary protein levels in OLETF rats

The body weights of OLETF rats were greater than those of LETO rats between 12 and 48 weeks; however, no significant differences were observed when compared with OLETF rats treated with FP. In addition, at weeks 52 and 56, body weight did not differ significantly among the groups ([Fig. 1A](#f1-etm-0-0-8188){ref-type="fig"}). Blood glucose levels for the LETO control rats did not change throughout the study period. Over the same period of time, age-matched OLETF rat blood glucose levels were statistically higher. The blood glucose levels of OLETF rats treated with FP also increased during the study period, with levels significantly different from those of the OLETF control group at weeks 40 and 52 ([Fig. 1B](#f1-etm-0-0-8188){ref-type="fig"}). Urinary protein levels in all OLETF rats gradually and continually increased during the entire study period compared with the levels in the LETO rats, which remained unchanged. OLETF rats treated with FP exhibited significantly lower 24-h urinary protein levels than those exhibited by the OLETF control group at weeks 24, 36 and 44 ([Fig. 1C](#f1-etm-0-0-8188){ref-type="fig"}).

### FP treatment ameliorates histological kidney changes in OLETF rats

Glomerular lesions in OLETF rats were characterized by hyalinosis, thickening of the basement membrane, mesangial expansion and sclerosis ([Fig. 2A](#f2-etm-0-0-8188){ref-type="fig"}). These pathological changes were more severe at 56 weeks of age than at 36 weeks. Interstitial fibrosis in OLETF rats was focal and mild at 36 weeks of age, whereas at 56 weeks of age severe changes occurred that included protein cast, tubular dilation or atrophy and infiltration of inflammatory cells ([Fig. 2A](#f2-etm-0-0-8188){ref-type="fig"}). Treatment with FP significantly ameliorated glomerulosclerosis in OLETF rats at both 36 and 56 weeks of age ([Fig. 2B](#f2-etm-0-0-8188){ref-type="fig"}), but was unable to attenuate the increase in interstitial fibrosis ([Fig. 2C](#f2-etm-0-0-8188){ref-type="fig"}).

### Comparative proteomic analysis of renal cortices from untreated and FP-treated OLETF rats

[Fig. 3](#f3-etm-0-0-8188){ref-type="fig"} displays representative 2-DE patterns of soluble and insoluble renal cortex proteins from untreated and FP-treated OLETF rats. Comparison of the protein profiles from the two groups identified that 9 protein spots (S1-S9) were differentially expressed in the soluble subproteome and 10 protein spots (I1-I10) were differentially expressed in the insoluble subproteome ([Fig. 4](#f4-etm-0-0-8188){ref-type="fig"}). These protein spots were submitted for MALDI-TOF MS analysis. All protein spots were successfully isolated and their PMF, protein name and related data were obtained in the corresponding database and are listed in [Table I](#tI-etm-0-0-8188){ref-type="table"}. Certain different protein spots were identified as the same protein, likely because of different translational or post-translational modifications leading to changes in physicochemical characteristics during protein expression, resulting in their separation into different protein spots in 2-DE. The differentially expression of Hspa9 and Gpx3 were further validated by western blot analysis. As shown in [Fig. 5](#f5-etm-0-0-8188){ref-type="fig"}, the expression levels of Hspa9 and Gpx3 at 56 weeks were similar to those observed in the 2-DE gels. The abundances of the proteins increased significantly in the renal cortex of OLETF rats treated with FP at 56 weeks.

DAVID analysis revealed over-representation of pathways and terms ([Table II](#tII-etm-0-0-8188){ref-type="table"}) in the differentially expressed proteins from this tissue. Specifically, 'glycolysis/gluconeogenesis' was over-represented among the identified KEGG pathways. 'Generation of precursor metabolites', 'energy, glucose metabolic process' and 'oxidation reduction' were over-represented in biological processes. Furthermore, differentially expressed proteins were over-represented in the mitochondrion and soluble fraction. Within these, there was over-representation of molecular functions including 'magnesium ion binding', 'selenium binding' and 'hydro-lyase activity'.

Discussion
==========

DN is a main cause of end-stage renal disease that currently has no effective treatment to block or reverse its pathological process. A number of clinical and basic studies have investigated ACEIs/angiotensin II receptor blockers ([@b24-etm-0-0-8188]--[@b26-etm-0-0-8188]) for the treatment of DN to delay the progression of the disease, and these drugs have been recommended by the Kidney Disease Outcomes Quality Initiative as first-line clinical treatments ([@b27-etm-0-0-8188]). However, studies have identified that ACEIs demonstrate some nephrotoxicity since ACEIs, including FP, may cause an exaggerated or progressive decline in renal function in conditions such as renal-artery stenosis ([@b28-etm-0-0-8188],[@b29-etm-0-0-8188]) and polycystic kidney disease ([@b30-etm-0-0-8188]), due to their preferential vasodilation of the renal efferent arteriole.

The present study determined that the ACEI drug FP reduced the pathological damage to renal tissue in OLETF rats and reduced urinary protein excretion. FP significantly inhibited the expression of KIM-1, an early marker of renal injury in OLETF rats ([Fig. S2](#SD1-etm-0-0-8188){ref-type="supplementary-material"}), indicating that FP exerts good renoprotective effects. *In vitro* experiments also confirmed that FP had a significant effect on the proliferation of NRK-52E cells at 13.32 µg/ml, which was \~119 times the maximum blood concentration in human (112±8 ng/ml; [Fig. S1](#SD1-etm-0-0-8188){ref-type="supplementary-material"}) ([@b31-etm-0-0-8188]), suggesting that FP improves diabetic kidney injury with no obvious nephrotoxic effects.

In the development of DN, proteinuria not only serves as an important marker for evaluating pathological progression but also participates in the development of renal fibrosis ([@b32-etm-0-0-8188]). Albumin and other proteins that appear in urine due to abnormal filtration, can interact with the glomerular mesangium and proximal tubule ([@b33-etm-0-0-8188]), which activates a wide array of intracellular signaling pathways, such as the ERK, NF-κB and protein kinase C pathways ([@b34-etm-0-0-8188]). This induces fibrotic substances, such as transforming growth factor-β, collagens, C-C motif chemokine 2 and metalloproteinase inhibitor 1 ([@b33-etm-0-0-8188],[@b35-etm-0-0-8188],[@b36-etm-0-0-8188]), and ultimately leads to fibrosis and loss of renal function ([@b37-etm-0-0-8188]). The present results demonstrated that FP alleviated proteinuria in OLETF rats, suggesting that this may have a role in improving diabetic glomerular sclerosis and tubulointerstitial fibrosis. Subsequent experiments investigating the renal cortex proteomics profile in OLETF rats determined that FP treatment resulted in significant changes in the abundance of 17 proteins, including Hspa9 and Gpx3. Bioinformatics analysis indicated that the function of these differentially expressed proteins likely participated in biological processes such as oxidative stress and glucose metabolism. Therefore, FP may have a renoprotective role by increasing the expression of Hspa9 to inhibit oxidative stress, consequently reducing tissue and cell damage.

In the present study, compared with the OLETF control, treatment with FP caused a significant increase in the abundance of the plasma glutathione peroxidase precursor Gpx3. Gpx comprises an important part of the antioxidant mechanism in body ([@b38-etm-0-0-8188],[@b39-etm-0-0-8188]) and is actively expressed in human kidney proximal tubule cells ([@b40-etm-0-0-8188]). Previous research determined that hyperglycemia induces the overproduction of superoxide by the mitochondrial electron transport chain, leading to an increase in ROS greater than the antioxidant capacity of the body, resulting in cell and tissue damage ([@b12-etm-0-0-8188]). In addition, high glucose can stimulate 12-lipoxygenasein podocytes, which also leads to oxidative stress through the generation of superoxide ([@b41-etm-0-0-8188]). Based on such observations, Brownlee ([@b12-etm-0-0-8188]) proposed that the overproduction of superoxide was likely to be a common mechanism for the pathogenesis of diabetic complications. Consistent with this, angiotensin II has been shown to induce ROS production and the activation of NF-κB and mitogen activated protein kinase in diabetic glomeruli and mesangial cells ([@b34-etm-0-0-8188]). As angiotensin II is an important medium of oxidative stress, studies have accordingly begun to explore the use of ACEIs for reducing oxidative stress levels in patients with DN. Notably, these trials have demonstrated that ACEIs and angiotensin II receptor blockers are able to reduce oxidative stress and inflammation in patients with DN and that this effect is independent of the antihypertensive effect ([@b42-etm-0-0-8188],[@b43-etm-0-0-8188]). It has been suggested that the specific mechanism may involve a reduction of oxidative stress-associated damage by blocking the NADPH oxidase pathway ([@b44-etm-0-0-8188]) by decreasing the elevation in ROS generation induced by platelet-derived growth factor ([@b45-etm-0-0-8188]). Another potential mechanism might involve attenuating apoptosis and intracellular ROS formation induced by angiotensin II through modulation of the toll like receptor 4/MYD88 innate immune signal transduction adaptor pathway ([@b46-etm-0-0-8188]). Furthermore, previous studies determined that Gpx3 interacts with podocin, which is used as a marker of podocytes ([@b47-etm-0-0-8188],[@b48-etm-0-0-8188]) and is associated with microalbuminuria in DN ([@b49-etm-0-0-8188]). Taken together, Gpx3 may serve an important role in the development of DN. In the present study, it was determined that FP treatment increased the Gpx3 precursor concentration in the renal cortex of OLETF rats. These results suggested that FP could inhibit the development of DN by stimulating increased Gpx3 expression.

The results of the present study also indicated that FP affected the expression of Hspa9, which has begun to attract attention regarding its role in the pathogenesis of DN ([@b50-etm-0-0-8188]). Hspa9 also known as glucose regulated protein 75, mortalin, mitochondria heat shock protein 70 and peptide binding protein 74, is mainly localized in the mitochondria, where it functions as a molecular chaperone, serving a central role in the elaborate translocation system for the efficient import and export of proteins and maintaining the function of the mitochondria ([@b51-etm-0-0-8188]). Mutations in Hspa9 cause the degeneration of nerve cells and have a role in the pathogenesis of Parkinson\'s disease ([@b52-etm-0-0-8188]). Hspa9 binds to p53 protein in the cytoplasm and inhibits its function acting as an anti-apoptotic factor. Consistent with this, Hspa9 is found to be upregulated in many human cancer types, suggesting its association with the occurrence and metastasis of malignant tumors ([@b53-etm-0-0-8188]). In addition, high levels of Hspa9 expression can protect the cell from a variety of stress-induced damage types, reducing the effects of various physical and chemical factors. For example, it has been shown that Hspa9 overexpression can reduce the damage to cells mediated by glucose deprivation and that the protective effect may be achieved by inhibiting the accumulation of ROS ([@b54-etm-0-0-8188]). The antioxidant function has also been confirmed by many other studies ([@b55-etm-0-0-8188]--[@b57-etm-0-0-8188]), including the normalization of high-glucose-induced enhanced ROS production through the endogenous overexpression of translocase of inner mitochondrial membrane (Tim)44 combined with facilitated import of antioxidative enzymes such as superoxide dismutase and GPx, as Tim44 forms a complex with Hspa9 and Tim23 to affect mitochondrial transmembrane transport ([@b55-etm-0-0-8188]). Other research has demonstrated that at the mRNA level, α-lipoic acid, a type of antioxidant, can increase the expression of Hspa9 in both streptozotocin-induced diabetic and non-diabetic rats ([@b58-etm-0-0-8188]). In addition, Hspa9 can integrate with podoplanin, which is mainly expressed in podocytes, indicating an important role of Hspa9 in development of DN ([@b59-etm-0-0-8188]). Furthermore, ACEIs can affect the expression of Hspa9, as has been demonstrated by a study where treatment with the ACEI captopril delayed the apoptotic tube collapse of bovine retinal endothelial cells and upregulated the level of Hspa9 expression in these cells ([@b60-etm-0-0-8188]). Taken together, it can be further hypothesized that the oxidative stress-inhibitory or renoprotective effects of ACEIs correlate with the upregulation of Hspa9 expression.

In conclusion, the present study determined that 17 proteins were significantly changed in the FP-treated kidney cortex. The increased expression levels of Hspa9 and Gpx3 following FP treatment were confirmed by western blot analysis These identified differentially expressed proteins may not only improve understanding of the mechanism of ACEIs in OLETF rats, but may also provide potential drug targets for the treatment of DN.
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![Histologic changes between LETO, OLETF and FP-treated OLETF rat kidneys. (A) Periodic acid-Schiff staining of renal glomeruli and tubules. (B) Glomerulosclerosis index. (C) Interstitial fibrosis index. Data are presented as the mean ± SD. \*P\<0.05 and \*\*P\<0.01 vs. respective OLETF group. LETO, Long-Evans Tokushima Otsuka; OLETF, Otsuka Long-Evans Tokushima Fatty; FP, fosinopril.](etm-19-01-0172-g01){#f2-etm-0-0-8188}
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![Differentially expressed proteins distribution in the (A) soluble and (B) insoluble subproteome shown by two-dimensional gel electrophoresis analysis.](etm-19-01-0172-g03){#f4-etm-0-0-8188}

![FP treatment increases Gpx3 and Hspa9 expression in OLETF rats. (A) Magnified comparison map of Gpx3 and Hspa9 in the subproteome (B) and western blot analysis of Gpx3 and Hspa9 expression in OLETF and FP-treated OLETF rat renal cortices. Data are presented as the mean ± SD. \*P\<0.05 with comparisons indicated by lines. Gpx3, glutathione peroxidase 3; Hspa9, heat shock protein family A member 9; OLETF, Otsuka Long-Evans Tokushima Fatty; FP, fosinopril.](etm-19-01-0172-g04){#f5-etm-0-0-8188}

###### 

Effect of fosinopril on the renal cortex protein expression profile of OLETF rats.

  Spot no.   GI no.          Protein name                                                            Gene name   Mass    Sequence coverage (%)   MOWSE score   Age, weeks   Protein abundance
  ---------- --------------- ----------------------------------------------------------------------- ----------- ------- ----------------------- ------------- ------------ -------------------
  S1         gi\|1000439     grp75                                                                   Hspa9       32/48   46                      239           36           N
                                                                                                                                                               56           ↑
  S2         gi\|40254595    Dihydropyrimidinase-                                                    Dpysl2      19/57   43                      108           36           ↓
                             related protein 2                                                                                                                 56           ↓
  S3         gi\|149030730   Selenium binding                                                        Selenbp1    11/35   35                      88            36           ↓
                             protein 2                                                                                                                         56           ↓
  S4         gi\|158186649   α-enolase                                                               Eno1        26/46   66                      222           36           ↓
                                                                                                                                                               56           N
  S5         gi\|40254752    Phosphoglycerate                                                        Pgk1        21/33   56                      204           36           N
                             kinase 1                                                                                                                          56           ↓
  S6         gi\|157823267   S-formylglutathione                                                     Esd         9/39    33                      62            36           N
                             hydrolase isoform a                                                                                                               56           ↑
  S7         gi\|51491893    Phenazine biosynthesis-                                                 Pbld1       10/21   32                      126           36           ↓
                             like domain-containing protein                                                                                                    56           ↓
  S8         gi\|6978515     Apolipoprotein A-I                                                      Apoa1       14/59   48                      83            36           N
                             preproprotein                                                                                                                     56           ↑
  S9         gi\|6723180     Plasma glutathione                                                      Gpx3        15/21   42                      136           36           ↑
                             peroxidase precursor                                                                                                              56           ↑
  I1         gi\|158186649   α-enolase                                                               Eno1        8/16    27                      80            36           N
                                                                                                                                                               56           ↑
  I2         gi\|51036635    Fructose-1,                                                             Fbp1        13/19   33                      144           36           N
                             6-bisphosphatase 1                                                                                                                56           ↑
  I3         gi\|170295834   NADH dehydrogenase                                                      Ndufa10     15/26   31                      175           36           ↑
                             \[ubiquinone\] 1 alpha subcomplex subunit 10, mitochondrial precursor                                                             56           ↑
  I4         gi\|170295834   NADH dehydrogenase                                                      Ndufa10     17/24   56                      241           36           ↓
                             \[ubiquinone\] 1 alpha subcomplex subunit 10, mitochondrial precursor                                                             56           N
  I5         gi\|56090293    Pyruvate Dehydrogenase                                                  Pdhb        16/33   34                      108           36           ↑
                             E1 component subunit beta, mitochondrial precursor                                                                                56           N
  I6         gi\|15100179    Malate dehydrogenase,                                                   Mdh1        10/16   30                      128           36           N
                             cytoplasmic isoform Mdh1                                                                                                          56           ↑
  I7         gi\|57527204    Electron transfer                                                       Etfa        20/54   58                      168           36           N
                             flavoprotein subunit alpha, mitochondrial precursor                                                                               56           ↓
  I8         gi\|24159081    Chain A, crystal structure                                              Echs1       21/40   56                      158           36           N
                             analysis of rat enoyl-Coa hydratase in complex with hexadienoyl-Coa                                                               56           ↓
  I9         gi\|68163417    Acylpyruvase FAHD1,                                                     Fahd1       10/17   32                      90            36           ↓
                             mitochondrial                                                                                                                     56           ↓
  I10        gi\|55926145    Nucleoside diphosphate                                                  Nme2        8/12    55                      102           36           N
                             kinase B                                                                                                                          56           ↓

Spot numbers were defined according to the spot positions in 2-DE gels. GI numbers are a series of digits assigned consecutively by the National Center for Biotechnology Information to each sequence as an identifier. Mass is the number of matched mass values/number of total mass values searched. Sequence coverage was calculated as the percentage of identified sequence to the complete sequence of the matched protein. The MOWSE score of the identified protein was calculated as −10\*Log (P), where P is the probability that the observed match is a random event. Changes in renal cortex protein abundance in OLETF rats treated with fosinopril compared with OLETF rats were as displayed on the 2-DE gels. N, no significant change; ↑, increased abundance; ↓, decreased abundance; S, soluble component; I, insoluble component; OLETF, Otsuka Long-Evans Tokushima Fatty; 2-DE, two-dimensional electrophoresis; MOWSE, Molecular Weight Search.

###### 

DAVID analysis of differentially expressed proteins in the kidney cortices of untreated and fosinopril-treated OLETF rats.

  Category                                    Term                                      Genes                                                          Count   Percentage   P-value
  ------------------------------------------- ----------------------------------------- -------------------------------------------------------------- ------- ------------ ----------
  KEGG pathway                                Glycolysis/gluconeogenesis                Fbp1, Pgk1, Pdhb, Eno1                                         4       25           0.0005
  Biological process metabolites and energy   Generation of precursor                   Ndufa10, Pgk1, Pdhb, Eno1, Etfa, Mdh1                          6       37.5         \<0.0001
  Biological process                          Glycolysis                                Pgk1, Pdhb, Eno1, Mdh1                                         4       25           \<0.0001
  Biological process                          Glucose metabolic process                 Fbp1, Pgk1, Pdhb, Eno1, Mdh1                                   5       31.25        \<0.0001
  Biological process                          Monosaccharide catabolic process          Pgk1, Pdhb, Eno1, Mdh1                                         4       25           \<0.0001
  Biological process                          Hexose metabolic process                  Fbp1, Pgk1, Pdhb, Eno1, Mdh1                                   5       31.25        \<0.0001
  Biological process                          Alcohol catabolic process                 Pgk1, Pdhb, Eno1, Mdh1                                         4       25           0.0001
  Biological process                          Cellular carbohydrate catabolic process   Pgk1, Pdhb, Eno1, Mdh1                                         4       25           0.0001
  Biological process                          Monosaccharide metabolic process          Fbp1, Pgk1, Pdhb, Eno1, Mdh1                                   5       31.25        0.0001
  Biological process                          Carbohydrate catabolic process            Pgk1, Pdhb, Eno1, Mdh1                                         4       25           0.0001
  Biological process                          Pyruvate metabolic process                Fbp1, Pgk1, Pdhb                                               3       18.75        0.0010
  Biological process                          Oxidation reduction                       Gpx3, Ndufa10, Pdhb, Etfa, Mdh1                                5       31.25        0.0032
  Biological process                          Coenzyme metabolic process                Gpx3, Pdhb, Mdh1                                               3       18.75        0.0123
  Biological process                          Cofactor metabolic process                Gpx3, Pdhb, Mdh1                                               3       18.75        0.0192
  Biological process                          Gluconeogenesis                           Fbp1, Pgk1                                                     2       12.5         0.0245
  Biological process                          Hexose biosynthetic process               Fbp1, Pgk1                                                     2       12.5         0.0287
  Biological process                          Monosaccharide biosynthetic process       Fbp1, Pgk1                                                     2       12.5         0.0370
  Biological process                          Acetyl-CoA metabolic process              Pdhb, Mdh1                                                     2       12.5         0.0401
  Biological process                          Alcohol biosynthetic process              Fbp1, Pgk1                                                     2       12.5         0.0463
  Biological process                          Response to drug                          Apoa1, Gpx3, Ndufa10                                           3       18.75        0.0467
  Subcellular localization                    Mitochondrial matrix                      Echs1, Ndufa10, Pdhb, Etfa, Hspa9                              5       31.25        0.0001
  Subcellular localization                    Mitochondrial lumen                       Echs1, Ndufa10, Pdhb, Etfa, Hspa9                              5       31.25        0.0001
  Subcellular localization                    Mitochondrion                             Fahd1, Nme2, Echs1, Dpysl2, Ndufa10, Pdhb, Etfa, Mdh1, Hspa9   9       56.25        0.0001
  Subcellular localization                    Soluble fraction                          Gpx3, Fbp1, Pgk1, Eno1, Mdh1                                   5       31.25        0.0006
  Subcellular localization                    Intracellular organelle lumen             Apoa1, Echs1, Ndufa10, Pdhb, Etfa, Hspa9                       6       37.5         0.0182
  Subcellular localization                    Organelle lumen                           Apoa1, Echs1, Ndufa10, Pdhb, Etfa, Hspa9                       6       37.5         0.0210
  Subcellular localization                    Membrane-enclosed lumen                   Apoa1, Echs1, Ndufa10, Pdhb, Etfa, Hspa9                       6       37.5         0.0235
  Molecular function                          Magnesium ion binding                     Fahd1, Nme2, Fbp1, Eno1                                        4       25           0.0044
  Molecular function                          Selenium binding                          Gpx3, Selenbp1                                                 2       12.5         0.0209
  Molecular function                          Hydro-lyase activity                      Echs1, Eno1                                                    2       12.5         0.0436

OLETF, Otsuka Long-Evans Tokushima Fatty; KEGG, Kyoto Encyclopedia of Genes and Genomes.
